Most Read Articles
Rachel Soon, 22 Mar 2019

At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.

18 Mar 2019
Aspirin use is associated with a lower risk of glioma, according to data from the Glioma International Case-Control Study.
11 Apr 2019
Overall, 5-fluorouracil is more effective than imiquimod in reducing the risk of keratinocyte carcinoma, but there are no differences in the short- or long-term risk of subsequent site-specific keratinocyte carcinoma in a real-world practice setting, according to a new study.
18 Feb 2019
Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.

Modified FOLFOX6 tied to better tolerability, higher completion rates vs CAPOX

12 Oct 2018

The combination of 5-fluorouracil and oxaliplatin (mFOLFOX6), the most commonly used adjuvant treatment option for stage IIB and stage III colon cancer in British Columbia, results in better tolerability and higher treatment completion rates relative to capecitabine plus oxaliplatin (CAPOX), according to a recent study.

Included in the analysis were patients (n=306) with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6. The authors collected protocol utilization rates, patient characteristics and toxicities of the two regimens and compared these by descriptive statistics.

The most commonly used regimen was mFOLFOX6, with a utilization rate of 69 percent. Patients in the CAPOX arm were younger (57 vs 62 years; p<0.01), but there were no other significant differences between the two groups.

Compared to CAPOX, mFOLFOX6 was associated with less dose-limiting toxicities (82 percent vs 95 percent; p<0.01). In addition, more patients completed the intended 24-week course of mFOLFOX6 compared to CAPOX (82 percent vs 67 percent; p<0.01).

However, a study by Ho and colleagues found that replacing mFOLFOX6 with CAPOX in the adjuvant treatment of colon cancer was associated with potential cost savings from the payer and societal perspectives. [Clin Colorectal Cancer 2016;15:158-163]

From the payer perspective, CAPOX use led to cost savings of $5,339 CAD per patient vs use of mFOLFOX6. From a societal perspective, CAPOX use resulted in savings of $6,080 CAD per patient. The biggest cost savings with CAPOX were attributed to fewer visits for chemotherapy treatment and reduced usage of the central venous access device. [Clin Colorectal Cancer 2016;15:158-163]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 22 Mar 2019

At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.

18 Mar 2019
Aspirin use is associated with a lower risk of glioma, according to data from the Glioma International Case-Control Study.
11 Apr 2019
Overall, 5-fluorouracil is more effective than imiquimod in reducing the risk of keratinocyte carcinoma, but there are no differences in the short- or long-term risk of subsequent site-specific keratinocyte carcinoma in a real-world practice setting, according to a new study.
18 Feb 2019
Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.